Hinge Health initiated with a Buy at Stifel

Stifel analyst David Grossman initiated coverage of Hinge Health (HNGE) with a Buy rating and $48 price target Hinge is a software platform that offers musculoskeletal care virtually via a mobile-phone app or messaging with licensed physical therapists and coaches, the analyst tells investors in a research note. The firm views the company as a high-teens low-20 percent revenue compounder near-term with expanding margins. Hinge turned profitable and free cash flow positive in 2024 “with significant opportunity for future margin expansion,” contends Stifel.